Within our polycistronic expression construct the expression of the four genes mdh, hps, phi and xpk is controlled by the constitutive promoter [http://parts.igem.org/Part:BBa_J23119 BBa_J23119]. To tune the expression levels of the genes for a more efficient expression system it is neccessary to control them seperately.
We decided to adjust the expression levels of the four genes by using well-characterized constitutive promoters with different strengths from the Anderson Promoter Library.
Since we do not know which promoter combination is best for the efficient expression of the methanol uptake pathway, we developed a straightforward cloning strategy to build a monocistronic diversity library using the RDP Assembly standard.
Design
The design of our monocistronic diversity library is mainly based on the RDP Assembly method by Synbiota. To better understand our design, we recommend to first read our detailed description about how the RDP assembly method works.
Because we expected the promoter [http://parts.igem.org/Part:BBa_J23119 BBa_J23119] to be the strongest within the Anderson Promoter Library, we chose this one to always control the bottleneck enzyme Mdh in our circuit design. Diversity is introduced by varying the promoters for the three remaining genes hps, phi and xpk. We decided on a set of four promoters from the Anderson Library:
- [http://parts.igem.org/Part:BBa_J23100 BBa_J23100]
- [http://parts.igem.org/Part:BBa_J23104 BBa_J23104]
- [http://parts.igem.org/Part:BBa_J23110 BBa_J23110]
- [http://parts.igem.org/Part:BBa_J23119 BBa_J23119]
These promoters cover a range from medium to very high in strength.
To minimize the genetic instability of our circuit [1], we designed it to have four different terminator sequences downstream to every CDS.
With three sites to introduce diversity in our circuit and (only) four different promoters, our resulting diversity library contains 43 = 64 variants. Obviously, it is nearly impossible for an iGEM team to clone every single variant seperately during one summer.
Our first step towards an efficient cloning strategy was to split up the circuit into RDP part fragments. To introduce diversity we first planed to add equimolar promoter RDP part mixes at the black labeled sites in the circuit.
But to reduce the assembly steps and increase the assembly efficiency we decided to respectively combine three RDP parts from the circuit to form three different precursor sets.
The picture below illustrates how we designed the assembly of our precursor sets.
In total, this strategy results in 12 different precursor plasmids:
Precursor |
description
|
BBa_K1585210.Trp*.BBa_J23100 |
mdh.AP00 precursor
|
BBa_K1585210.Trp*.BBa_J23104 |
mdh.AP04 precursor
|
BBa_K1585210.Trp*.BBa_J23110 |
mdh.AP10 precursor
|
BBa_K1585210.Trp*.BBa_J23119 |
mdh.AP19 precursor
|
BBa_K1585211.BBa_B1006.BBa_J23100 |
hps.AP00 precursor
|
BBa_K1585211.BBa_B1006.BBa_J23104 |
hps.AP04 precursor
|
BBa_K1585211.BBa_B1006.BBa_J23110 |
hps.AP10 precursor
|
BBa_K1585211.BBa_B1006.BBa_J23119 |
hps.AP19 precursor
|
BBa_K1585212.BBa_B1002.BBa_J23100 |
phi.AP00 precursor
|
BBa_K1585212.BBa_B1002.BBa_J23104 |
phi.AP04 precursor
|
BBa_K1585212.BBa_B1002.BBa_J23110 |
phi.AP10 precursor
|
BBa_K1585212.BBa_B1002.BBa_J23119 |
phi.AP19 precursor
|
The resulting precursor plasmids have to be purified and cut with BsaI and NotI to convert them into new RDP parts. To prevent complications, we chose chloramphenicol as resistance marker for the precursor plasmids. Since we planed to use kanamycin as resistance marker in the monocistronic diversity library, the cut backbone fragments of the precursor plasmids would not lead to viable clones.
In the end, this is how the design of the final assembly of the monocistronic diversity library looks like: We introduce diversity by adding the precursor RDP parts of one type in equimolar amounts to the reaction.
The resulting assembly product is supposed to be transformed into an appropriate expression strain (e.g. E. coli BL21 Gold DE3).
Results
The following table gives an overview on our achieved progress in creating precursor plasmids:
- Failure = no valid plasmid sequenced
- Success = a valid plasmid without mutations was sequenced
Precursor |
Results |
Plasmid ID
|
BBa_K1585210.Trp*.BBa_J23100 |
Failure |
-
|
BBa_K1585210.Trp*.BBa_J23104 |
Success |
#OX44#
|
BBa_K1585210.Trp*.BBa_J23110 |
Failure |
-
|
BBa_K1585210.Trp*.BBa_J23119 |
Success |
#DNRY#
|
BBa_K1585211.BBa_B1006.BBa_J23100 |
Success |
#ERZK#
|
BBa_K1585211.BBa_B1006.BBa_J23104 |
Failure |
-
|
BBa_K1585211.BBa_B1006.BBa_J23110 |
Failure |
-
|
BBa_K1585211.BBa_B1006.BBa_J23119 |
Failure |
-
|
BBa_K1585212.BBa_B1002.BBa_J23100 |
Success |
#931O#
|
BBa_K1585212.BBa_B1002.BBa_J23104 |
Success |
#EZYZ#
|
BBa_K1585212.BBa_B1002.BBa_J23110 |
Success |
#XW1Y#
|
BBa_K1585212.BBa_B1002.BBa_J23119 |
Success |
#RABS#
|
- *Trp = trp terminator, RDP part provided by Synbiota
Although we successfully created all required basic RDP parts, we were not able to create all the precursor RDP parts to continue with the assembly of the diversity library. In fact, we did not have problems to assemble the precursors. The major problem we had to face were mutations within the promoter sequences.
Synbiota recommends to use HPLC purified oligos for creating your own RDP part below 100 bp in length, but since we had to create lots of RDP parts and a limited budget, we decided to order mostly standard desalting oligos. This might be a reason, why many of our promoter sequences showed deletions and/or point mutations.
A more detailed documentation about creating the RDP parts and sequencing results can be found under:
Laboratory Notebook
Outlook
After characterizing the Mdh activity in our polycistronic strain and considering it's reduced growth rate, we think that the monocistronic expression strategy is worth exploring.
References
- ↑ Jack BR, Leonard SP, Mishler DM, Renda BA, Leon D, Suárez GA, Barrick JE. Predicting the Genetic Stability of Engineered DNA Sequences with the EFM Calculator. ACS Synth Biol. 2015 Aug 21;4(8):939-43. doi: 10.1021/acssynbio.5b00068. Epub 2015 Jul 1. PubMed PMID: 26096262.